Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care in newly diagnosed disease or in patients with ear...
Main Authors: | Christie P. M. Verkleij, Wassilis S. C. Bruins, Sonja Zweegman, Niels W. C. J. van de Donk |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Hemato |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-6357/2/1/7 |
Similar Items
-
Targeted Therapy With Immunoconjugates for Multiple Myeloma
by: Wassilis S. C. Bruins, et al.
Published: (2020-06-01) -
Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
by: Omar Castaneda-Puglianini, et al.
Published: (2021-09-01) -
Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
by: Gregorio Barilà, et al.
Published: (2021-01-01) -
Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
by: Mattia D’Agostino, et al.
Published: (2020-11-01) -
Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
by: Xiang Zhou, et al.
Published: (2020-07-01)